nodes	percent_of_prediction	percent_of_DWPC	metapath
Mifepristone—ABCC1—Mitoxantrone—lymphatic system cancer	0.174	0.211	CbGbCtD
Mifepristone—ABCC1—Vincristine—lymphatic system cancer	0.12	0.145	CbGbCtD
Mifepristone—CYP3A5—Teniposide—lymphatic system cancer	0.0924	0.112	CbGbCtD
Mifepristone—ABCC1—Methotrexate—lymphatic system cancer	0.0726	0.0879	CbGbCtD
Mifepristone—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0593	0.0718	CbGbCtD
Mifepristone—CYP3A7—Vincristine—lymphatic system cancer	0.0593	0.0718	CbGbCtD
Mifepristone—CYP3A5—Vincristine—lymphatic system cancer	0.0445	0.0538	CbGbCtD
Mifepristone—ABCB1—Mitoxantrone—lymphatic system cancer	0.042	0.0509	CbGbCtD
Mifepristone—CYP3A4—Cytarabine—lymphatic system cancer	0.0366	0.0443	CbGbCtD
Mifepristone—CYP3A4—Teniposide—lymphatic system cancer	0.036	0.0436	CbGbCtD
Mifepristone—ABCB1—Vincristine—lymphatic system cancer	0.0289	0.035	CbGbCtD
Mifepristone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0252	0.0305	CbGbCtD
Mifepristone—ABCB1—Methotrexate—lymphatic system cancer	0.0175	0.0212	CbGbCtD
Mifepristone—CYP3A4—Vincristine—lymphatic system cancer	0.0173	0.021	CbGbCtD
Mifepristone—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.00186	0.0107	CcSEcCtD
Mifepristone—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00157	0.009	CcSEcCtD
Mifepristone—Haemoglobin—Teniposide—lymphatic system cancer	0.00138	0.00791	CcSEcCtD
Mifepristone—Haemorrhage—Teniposide—lymphatic system cancer	0.00137	0.00787	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00137	0.00785	CcSEcCtD
Mifepristone—Infection—Mechlorethamine—lymphatic system cancer	0.00131	0.00753	CcSEcCtD
Mifepristone—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00128	0.00736	CcSEcCtD
Mifepristone—Anorexia—Mechlorethamine—lymphatic system cancer	0.00126	0.00723	CcSEcCtD
Mifepristone—Sinusitis—Fludarabine—lymphatic system cancer	0.00126	0.00722	CcSEcCtD
Mifepristone—Chills—Teniposide—lymphatic system cancer	0.00123	0.00706	CcSEcCtD
Mifepristone—Haemoglobin—Fludarabine—lymphatic system cancer	0.00121	0.00695	CcSEcCtD
Mifepristone—Haemorrhage—Fludarabine—lymphatic system cancer	0.00121	0.00691	CcSEcCtD
Mifepristone—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00115	0.00659	CcSEcCtD
Mifepristone—Chills—Fludarabine—lymphatic system cancer	0.00108	0.0062	CcSEcCtD
Mifepristone—Pain in extremity—Vincristine—lymphatic system cancer	0.00106	0.00611	CcSEcCtD
Mifepristone—Malnutrition—Fludarabine—lymphatic system cancer	0.00105	0.00602	CcSEcCtD
Mifepristone—Hypertension—Teniposide—lymphatic system cancer	0.00103	0.00591	CcSEcCtD
Mifepristone—Hypokalaemia—Carmustine—lymphatic system cancer	0.00101	0.00582	CcSEcCtD
Mifepristone—Muscular weakness—Carmustine—lymphatic system cancer	0.000983	0.00564	CcSEcCtD
Mifepristone—Oedema—Teniposide—lymphatic system cancer	0.000974	0.00559	CcSEcCtD
Mifepristone—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000974	0.00558	CcSEcCtD
Mifepristone—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.000973	0.00558	CcSEcCtD
Mifepristone—Infection—Teniposide—lymphatic system cancer	0.000968	0.00555	CcSEcCtD
Mifepristone—Malaise—Fludarabine—lymphatic system cancer	0.000946	0.00543	CcSEcCtD
Mifepristone—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.000943	0.00541	CcSEcCtD
Mifepristone—Muscular weakness—Vincristine—lymphatic system cancer	0.000939	0.00538	CcSEcCtD
Mifepristone—Pruritus—Mechlorethamine—lymphatic system cancer	0.000935	0.00536	CcSEcCtD
Mifepristone—Anorexia—Teniposide—lymphatic system cancer	0.000929	0.00533	CcSEcCtD
Mifepristone—Hypotension—Teniposide—lymphatic system cancer	0.00091	0.00522	CcSEcCtD
Mifepristone—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000904	0.00519	CcSEcCtD
Mifepristone—Arthralgia—Fludarabine—lymphatic system cancer	0.000893	0.00512	CcSEcCtD
Mifepristone—Myalgia—Fludarabine—lymphatic system cancer	0.000893	0.00512	CcSEcCtD
Mifepristone—Haemoglobin—Bleomycin—lymphatic system cancer	0.000888	0.00509	CcSEcCtD
Mifepristone—Haemorrhage—Bleomycin—lymphatic system cancer	0.000884	0.00507	CcSEcCtD
Mifepristone—Discomfort—Fludarabine—lymphatic system cancer	0.000882	0.00506	CcSEcCtD
Mifepristone—Dyspnoea—Teniposide—lymphatic system cancer	0.000869	0.00498	CcSEcCtD
Mifepristone—Oedema—Fludarabine—lymphatic system cancer	0.000856	0.00491	CcSEcCtD
Mifepristone—Infection—Fludarabine—lymphatic system cancer	0.000851	0.00488	CcSEcCtD
Mifepristone—Decreased appetite—Teniposide—lymphatic system cancer	0.000847	0.00486	CcSEcCtD
Mifepristone—Vomiting—Mechlorethamine—lymphatic system cancer	0.00084	0.00482	CcSEcCtD
Mifepristone—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00084	0.00482	CcSEcCtD
Mifepristone—Rash—Mechlorethamine—lymphatic system cancer	0.000833	0.00478	CcSEcCtD
Mifepristone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000832	0.00477	CcSEcCtD
Mifepristone—Anorexia—Fludarabine—lymphatic system cancer	0.000816	0.00468	CcSEcCtD
Mifepristone—Feeling abnormal—Teniposide—lymphatic system cancer	0.000803	0.0046	CcSEcCtD
Mifepristone—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000797	0.00457	CcSEcCtD
Mifepristone—Chills—Bleomycin—lymphatic system cancer	0.000793	0.00455	CcSEcCtD
Mifepristone—Nausea—Mechlorethamine—lymphatic system cancer	0.000785	0.0045	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00078	0.00447	CcSEcCtD
Mifepristone—Haemoglobin—Carmustine—lymphatic system cancer	0.000775	0.00445	CcSEcCtD
Mifepristone—Urticaria—Teniposide—lymphatic system cancer	0.000774	0.00444	CcSEcCtD
Mifepristone—Haemorrhage—Carmustine—lymphatic system cancer	0.000771	0.00442	CcSEcCtD
Mifepristone—Abdominal pain—Teniposide—lymphatic system cancer	0.00077	0.00442	CcSEcCtD
Mifepristone—Body temperature increased—Teniposide—lymphatic system cancer	0.00077	0.00442	CcSEcCtD
Mifepristone—Dyspnoea—Fludarabine—lymphatic system cancer	0.000763	0.00438	CcSEcCtD
Mifepristone—Oedema peripheral—Carmustine—lymphatic system cancer	0.00076	0.00436	CcSEcCtD
Mifepristone—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000758	0.00435	CcSEcCtD
Mifepristone—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000749	0.0043	CcSEcCtD
Mifepristone—Decreased appetite—Fludarabine—lymphatic system cancer	0.000744	0.00427	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000739	0.00424	CcSEcCtD
Mifepristone—Fatigue—Fludarabine—lymphatic system cancer	0.000738	0.00423	CcSEcCtD
Mifepristone—Pain—Fludarabine—lymphatic system cancer	0.000732	0.0042	CcSEcCtD
Mifepristone—Constipation—Fludarabine—lymphatic system cancer	0.000732	0.0042	CcSEcCtD
Mifepristone—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000724	0.00415	CcSEcCtD
Mifepristone—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000721	0.00413	CcSEcCtD
Mifepristone—Hypersensitivity—Teniposide—lymphatic system cancer	0.000718	0.00412	CcSEcCtD
Mifepristone—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000717	0.00411	CcSEcCtD
Mifepristone—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000714	0.00409	CcSEcCtD
Mifepristone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000706	0.00405	CcSEcCtD
Mifepristone—Asthenia—Teniposide—lymphatic system cancer	0.000699	0.00401	CcSEcCtD
Mifepristone—Malaise—Bleomycin—lymphatic system cancer	0.000694	0.00398	CcSEcCtD
Mifepristone—Pruritus—Teniposide—lymphatic system cancer	0.000689	0.00395	CcSEcCtD
Mifepristone—Body temperature increased—Fludarabine—lymphatic system cancer	0.000677	0.00388	CcSEcCtD
Mifepristone—Mental disorder—Carmustine—lymphatic system cancer	0.000676	0.00388	CcSEcCtD
Mifepristone—Malnutrition—Carmustine—lymphatic system cancer	0.000671	0.00385	CcSEcCtD
Mifepristone—Angiopathy—Vincristine—lymphatic system cancer	0.000668	0.00383	CcSEcCtD
Mifepristone—Diarrhoea—Teniposide—lymphatic system cancer	0.000667	0.00382	CcSEcCtD
Mifepristone—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000664	0.00381	CcSEcCtD
Mifepristone—Myalgia—Bleomycin—lymphatic system cancer	0.000655	0.00376	CcSEcCtD
Mifepristone—Back pain—Carmustine—lymphatic system cancer	0.000649	0.00373	CcSEcCtD
Mifepristone—Discomfort—Bleomycin—lymphatic system cancer	0.000647	0.00371	CcSEcCtD
Mifepristone—Mental disorder—Vincristine—lymphatic system cancer	0.000645	0.0037	CcSEcCtD
Mifepristone—Chills—Mitoxantrone—lymphatic system cancer	0.000643	0.00369	CcSEcCtD
Mifepristone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000631	0.00362	CcSEcCtD
Mifepristone—Oedema—Bleomycin—lymphatic system cancer	0.000628	0.0036	CcSEcCtD
Mifepristone—Infection—Bleomycin—lymphatic system cancer	0.000624	0.00358	CcSEcCtD
Mifepristone—Back pain—Vincristine—lymphatic system cancer	0.00062	0.00356	CcSEcCtD
Mifepristone—Vomiting—Teniposide—lymphatic system cancer	0.000619	0.00355	CcSEcCtD
Mifepristone—Asthenia—Fludarabine—lymphatic system cancer	0.000614	0.00352	CcSEcCtD
Mifepristone—Rash—Teniposide—lymphatic system cancer	0.000614	0.00352	CcSEcCtD
Mifepristone—Dermatitis—Teniposide—lymphatic system cancer	0.000614	0.00352	CcSEcCtD
Mifepristone—Headache—Teniposide—lymphatic system cancer	0.00061	0.0035	CcSEcCtD
Mifepristone—Pruritus—Fludarabine—lymphatic system cancer	0.000606	0.00347	CcSEcCtD
Mifepristone—Back pain—Mitoxantrone—lymphatic system cancer	0.000604	0.00346	CcSEcCtD
Mifepristone—Anorexia—Bleomycin—lymphatic system cancer	0.000598	0.00343	CcSEcCtD
Mifepristone—Hypotension—Bleomycin—lymphatic system cancer	0.000587	0.00336	CcSEcCtD
Mifepristone—Diarrhoea—Fludarabine—lymphatic system cancer	0.000586	0.00336	CcSEcCtD
Mifepristone—Hypertension—Carmustine—lymphatic system cancer	0.00058	0.00333	CcSEcCtD
Mifepristone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000579	0.00332	CcSEcCtD
Mifepristone—Nausea—Teniposide—lymphatic system cancer	0.000579	0.00332	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000572	0.00328	CcSEcCtD
Mifepristone—Myalgia—Carmustine—lymphatic system cancer	0.000572	0.00328	CcSEcCtD
Mifepristone—Anxiety—Carmustine—lymphatic system cancer	0.00057	0.00327	CcSEcCtD
Mifepristone—Malaise—Mitoxantrone—lymphatic system cancer	0.000563	0.00323	CcSEcCtD
Mifepristone—Dyspnoea—Bleomycin—lymphatic system cancer	0.00056	0.00321	CcSEcCtD
Mifepristone—Hypertension—Vincristine—lymphatic system cancer	0.000553	0.00317	CcSEcCtD
Mifepristone—Oedema—Carmustine—lymphatic system cancer	0.000548	0.00314	CcSEcCtD
Mifepristone—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000547	0.00314	CcSEcCtD
Mifepristone—Decreased appetite—Bleomycin—lymphatic system cancer	0.000546	0.00313	CcSEcCtD
Mifepristone—Myalgia—Vincristine—lymphatic system cancer	0.000546	0.00313	CcSEcCtD
Mifepristone—Infection—Carmustine—lymphatic system cancer	0.000544	0.00312	CcSEcCtD
Mifepristone—Vomiting—Fludarabine—lymphatic system cancer	0.000544	0.00312	CcSEcCtD
Mifepristone—Rash—Fludarabine—lymphatic system cancer	0.00054	0.0031	CcSEcCtD
Mifepristone—Dermatitis—Fludarabine—lymphatic system cancer	0.000539	0.00309	CcSEcCtD
Mifepristone—Hypertension—Mitoxantrone—lymphatic system cancer	0.000539	0.00309	CcSEcCtD
Mifepristone—Pain—Bleomycin—lymphatic system cancer	0.000537	0.00308	CcSEcCtD
Mifepristone—Headache—Fludarabine—lymphatic system cancer	0.000536	0.00308	CcSEcCtD
Mifepristone—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000531	0.00305	CcSEcCtD
Mifepristone—Myalgia—Mitoxantrone—lymphatic system cancer	0.000531	0.00305	CcSEcCtD
Mifepristone—Anxiety—Mitoxantrone—lymphatic system cancer	0.00053	0.00304	CcSEcCtD
Mifepristone—Discomfort—Mitoxantrone—lymphatic system cancer	0.000525	0.00301	CcSEcCtD
Mifepristone—Oedema—Vincristine—lymphatic system cancer	0.000523	0.003	CcSEcCtD
Mifepristone—Anorexia—Carmustine—lymphatic system cancer	0.000522	0.003	CcSEcCtD
Mifepristone—Infection—Vincristine—lymphatic system cancer	0.00052	0.00298	CcSEcCtD
Mifepristone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000517	0.00297	CcSEcCtD
Mifepristone—Nervous system disorder—Vincristine—lymphatic system cancer	0.000513	0.00294	CcSEcCtD
Mifepristone—Hypotension—Carmustine—lymphatic system cancer	0.000512	0.00294	CcSEcCtD
Mifepristone—Oedema—Mitoxantrone—lymphatic system cancer	0.000509	0.00292	CcSEcCtD
Mifepristone—Nausea—Fludarabine—lymphatic system cancer	0.000509	0.00292	CcSEcCtD
Mifepristone—Infection—Mitoxantrone—lymphatic system cancer	0.000506	0.0029	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000499	0.00286	CcSEcCtD
Mifepristone—Urticaria—Bleomycin—lymphatic system cancer	0.000499	0.00286	CcSEcCtD
Mifepristone—Anorexia—Vincristine—lymphatic system cancer	0.000499	0.00286	CcSEcCtD
Mifepristone—Body temperature increased—Bleomycin—lymphatic system cancer	0.000496	0.00285	CcSEcCtD
Mifepristone—Insomnia—Carmustine—lymphatic system cancer	0.000496	0.00284	CcSEcCtD
Mifepristone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000495	0.00284	CcSEcCtD
Mifepristone—Hypotension—Vincristine—lymphatic system cancer	0.000489	0.0028	CcSEcCtD
Mifepristone—Dyspnoea—Carmustine—lymphatic system cancer	0.000489	0.0028	CcSEcCtD
Mifepristone—Somnolence—Carmustine—lymphatic system cancer	0.000487	0.00279	CcSEcCtD
Mifepristone—Anorexia—Mitoxantrone—lymphatic system cancer	0.000486	0.00279	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000477	0.00273	CcSEcCtD
Mifepristone—Decreased appetite—Carmustine—lymphatic system cancer	0.000476	0.00273	CcSEcCtD
Mifepristone—Hypotension—Mitoxantrone—lymphatic system cancer	0.000476	0.00273	CcSEcCtD
Mifepristone—Insomnia—Vincristine—lymphatic system cancer	0.000473	0.00271	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000473	0.00271	CcSEcCtD
Mifepristone—Constipation—Carmustine—lymphatic system cancer	0.000469	0.00269	CcSEcCtD
Mifepristone—Pain—Carmustine—lymphatic system cancer	0.000469	0.00269	CcSEcCtD
Mifepristone—Breast disorder—Methotrexate—lymphatic system cancer	0.000467	0.00268	CcSEcCtD
Mifepristone—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000465	0.00267	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000464	0.00266	CcSEcCtD
Mifepristone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000463	0.00265	CcSEcCtD
Mifepristone—Decreased appetite—Vincristine—lymphatic system cancer	0.000455	0.00261	CcSEcCtD
Mifepristone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000454	0.00261	CcSEcCtD
Mifepristone—Somnolence—Mitoxantrone—lymphatic system cancer	0.000453	0.0026	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000452	0.00259	CcSEcCtD
Mifepristone—Feeling abnormal—Carmustine—lymphatic system cancer	0.000452	0.00259	CcSEcCtD
Mifepristone—Fatigue—Vincristine—lymphatic system cancer	0.000451	0.00259	CcSEcCtD
Mifepristone—Asthenia—Bleomycin—lymphatic system cancer	0.00045	0.00258	CcSEcCtD
Mifepristone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000448	0.00257	CcSEcCtD
Mifepristone—Pain—Vincristine—lymphatic system cancer	0.000447	0.00257	CcSEcCtD
Mifepristone—Constipation—Vincristine—lymphatic system cancer	0.000447	0.00257	CcSEcCtD
Mifepristone—Pruritus—Bleomycin—lymphatic system cancer	0.000444	0.00255	CcSEcCtD
Mifepristone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000443	0.00254	CcSEcCtD
Mifepristone—Fatigue—Mitoxantrone—lymphatic system cancer	0.000439	0.00252	CcSEcCtD
Mifepristone—Constipation—Mitoxantrone—lymphatic system cancer	0.000436	0.0025	CcSEcCtD
Mifepristone—Pain—Mitoxantrone—lymphatic system cancer	0.000436	0.0025	CcSEcCtD
Mifepristone—Body temperature increased—Carmustine—lymphatic system cancer	0.000433	0.00248	CcSEcCtD
Mifepristone—Abdominal pain—Carmustine—lymphatic system cancer	0.000433	0.00248	CcSEcCtD
Mifepristone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000428	0.00245	CcSEcCtD
Mifepristone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00042	0.00241	CcSEcCtD
Mifepristone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000417	0.00239	CcSEcCtD
Mifepristone—Abdominal pain—Vincristine—lymphatic system cancer	0.000414	0.00237	CcSEcCtD
Mifepristone—Body temperature increased—Vincristine—lymphatic system cancer	0.000414	0.00237	CcSEcCtD
Mifepristone—Urticaria—Mitoxantrone—lymphatic system cancer	0.000405	0.00232	CcSEcCtD
Mifepristone—Hypersensitivity—Carmustine—lymphatic system cancer	0.000404	0.00232	CcSEcCtD
Mifepristone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000403	0.00231	CcSEcCtD
Mifepristone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000403	0.00231	CcSEcCtD
Mifepristone—Vomiting—Bleomycin—lymphatic system cancer	0.000399	0.00229	CcSEcCtD
Mifepristone—Infestation NOS—Methotrexate—lymphatic system cancer	0.000398	0.00228	CcSEcCtD
Mifepristone—Infestation—Methotrexate—lymphatic system cancer	0.000398	0.00228	CcSEcCtD
Mifepristone—Rash—Bleomycin—lymphatic system cancer	0.000396	0.00227	CcSEcCtD
Mifepristone—Dermatitis—Bleomycin—lymphatic system cancer	0.000395	0.00227	CcSEcCtD
Mifepristone—Asthenia—Carmustine—lymphatic system cancer	0.000393	0.00226	CcSEcCtD
Mifepristone—Hypersensitivity—Vincristine—lymphatic system cancer	0.000385	0.00221	CcSEcCtD
Mifepristone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000375	0.00215	CcSEcCtD
Mifepristone—Asthenia—Vincristine—lymphatic system cancer	0.000375	0.00215	CcSEcCtD
Mifepristone—Diarrhoea—Carmustine—lymphatic system cancer	0.000375	0.00215	CcSEcCtD
Mifepristone—Nausea—Bleomycin—lymphatic system cancer	0.000373	0.00214	CcSEcCtD
Mifepristone—Asthenia—Mitoxantrone—lymphatic system cancer	0.000366	0.0021	CcSEcCtD
Mifepristone—Dizziness—Carmustine—lymphatic system cancer	0.000362	0.00208	CcSEcCtD
Mifepristone—Haemoglobin—Methotrexate—lymphatic system cancer	0.000359	0.00206	CcSEcCtD
Mifepristone—Diarrhoea—Vincristine—lymphatic system cancer	0.000358	0.00205	CcSEcCtD
Mifepristone—Haemorrhage—Methotrexate—lymphatic system cancer	0.000357	0.00205	CcSEcCtD
Mifepristone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000349	0.002	CcSEcCtD
Mifepristone—Vomiting—Carmustine—lymphatic system cancer	0.000348	0.002	CcSEcCtD
Mifepristone—Dizziness—Vincristine—lymphatic system cancer	0.000346	0.00198	CcSEcCtD
Mifepristone—Rash—Carmustine—lymphatic system cancer	0.000346	0.00198	CcSEcCtD
Mifepristone—Dermatitis—Carmustine—lymphatic system cancer	0.000345	0.00198	CcSEcCtD
Mifepristone—Headache—Carmustine—lymphatic system cancer	0.000343	0.00197	CcSEcCtD
Mifepristone—Vomiting—Vincristine—lymphatic system cancer	0.000333	0.00191	CcSEcCtD
Mifepristone—Rash—Vincristine—lymphatic system cancer	0.00033	0.00189	CcSEcCtD
Mifepristone—Dermatitis—Vincristine—lymphatic system cancer	0.00033	0.00189	CcSEcCtD
Mifepristone—Headache—Vincristine—lymphatic system cancer	0.000328	0.00188	CcSEcCtD
Mifepristone—Nausea—Carmustine—lymphatic system cancer	0.000325	0.00187	CcSEcCtD
Mifepristone—Angiopathy—Methotrexate—lymphatic system cancer	0.000324	0.00186	CcSEcCtD
Mifepristone—Vomiting—Mitoxantrone—lymphatic system cancer	0.000324	0.00186	CcSEcCtD
Mifepristone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000322	0.00185	CcSEcCtD
Mifepristone—Rash—Mitoxantrone—lymphatic system cancer	0.000321	0.00184	CcSEcCtD
Mifepristone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000321	0.00184	CcSEcCtD
Mifepristone—Chills—Methotrexate—lymphatic system cancer	0.000321	0.00184	CcSEcCtD
Mifepristone—Headache—Mitoxantrone—lymphatic system cancer	0.000319	0.00183	CcSEcCtD
Mifepristone—Mental disorder—Methotrexate—lymphatic system cancer	0.000313	0.0018	CcSEcCtD
Mifepristone—Malnutrition—Methotrexate—lymphatic system cancer	0.000311	0.00178	CcSEcCtD
Mifepristone—Nausea—Vincristine—lymphatic system cancer	0.000311	0.00178	CcSEcCtD
Mifepristone—Nausea—Mitoxantrone—lymphatic system cancer	0.000303	0.00174	CcSEcCtD
Mifepristone—Back pain—Methotrexate—lymphatic system cancer	0.000301	0.00173	CcSEcCtD
Mifepristone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000289	0.00166	CcSEcCtD
Mifepristone—Malaise—Methotrexate—lymphatic system cancer	0.00028	0.00161	CcSEcCtD
Mifepristone—Arthralgia—Methotrexate—lymphatic system cancer	0.000265	0.00152	CcSEcCtD
Mifepristone—Myalgia—Methotrexate—lymphatic system cancer	0.000265	0.00152	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000263	0.00151	CcSEcCtD
Mifepristone—Discomfort—Methotrexate—lymphatic system cancer	0.000262	0.0015	CcSEcCtD
Mifepristone—Infection—Methotrexate—lymphatic system cancer	0.000252	0.00145	CcSEcCtD
Mifepristone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000249	0.00143	CcSEcCtD
Mifepristone—Skin disorder—Methotrexate—lymphatic system cancer	0.000247	0.00141	CcSEcCtD
Mifepristone—Anorexia—Methotrexate—lymphatic system cancer	0.000242	0.00139	CcSEcCtD
Mifepristone—Hypotension—Methotrexate—lymphatic system cancer	0.000237	0.00136	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000231	0.00133	CcSEcCtD
Mifepristone—Insomnia—Methotrexate—lymphatic system cancer	0.00023	0.00132	CcSEcCtD
Mifepristone—Dyspnoea—Methotrexate—lymphatic system cancer	0.000226	0.0013	CcSEcCtD
Mifepristone—Somnolence—Methotrexate—lymphatic system cancer	0.000226	0.00129	CcSEcCtD
Mifepristone—Decreased appetite—Methotrexate—lymphatic system cancer	0.000221	0.00127	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000219	0.00126	CcSEcCtD
Mifepristone—Fatigue—Methotrexate—lymphatic system cancer	0.000219	0.00126	CcSEcCtD
Mifepristone—Pain—Methotrexate—lymphatic system cancer	0.000217	0.00125	CcSEcCtD
Mifepristone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000209	0.0012	CcSEcCtD
Mifepristone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000208	0.00119	CcSEcCtD
Mifepristone—Urticaria—Methotrexate—lymphatic system cancer	0.000202	0.00116	CcSEcCtD
Mifepristone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000201	0.00115	CcSEcCtD
Mifepristone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000201	0.00115	CcSEcCtD
Mifepristone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000187	0.00107	CcSEcCtD
Mifepristone—Asthenia—Methotrexate—lymphatic system cancer	0.000182	0.00104	CcSEcCtD
Mifepristone—Pruritus—Methotrexate—lymphatic system cancer	0.00018	0.00103	CcSEcCtD
Mifepristone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000174	0.000996	CcSEcCtD
Mifepristone—Dizziness—Methotrexate—lymphatic system cancer	0.000168	0.000963	CcSEcCtD
Mifepristone—Vomiting—Methotrexate—lymphatic system cancer	0.000161	0.000926	CcSEcCtD
Mifepristone—Rash—Methotrexate—lymphatic system cancer	0.00016	0.000918	CcSEcCtD
Mifepristone—Dermatitis—Methotrexate—lymphatic system cancer	0.00016	0.000917	CcSEcCtD
Mifepristone—Headache—Methotrexate—lymphatic system cancer	0.000159	0.000912	CcSEcCtD
Mifepristone—Nausea—Methotrexate—lymphatic system cancer	0.000151	0.000865	CcSEcCtD
